Purpose: To report the ocular manifestations of phospholipase-Cg2associated antibody deficiency and immune dysregulation (PLAID).
P hospholipase-Cg2 (PLCg2)-Associated Antibody Deficiency and Immune Dysregulation (PLAID) is a rare inherited disease with a presentation that includes both autoinflammation and immunodeficiency. The few familial identified cases of PLAID show mutations in the PLCg2 gene leading to aberrant function of immune cells and overproduction of interleukin-1 b (IL-1b). Clinical manifestations encompass inflammation in multiple tissues, including recurrent skin eruptions, nonspecific interstitial pneumonitis and bronchiolitis, sinopulmonary infections, and arthralgia. 1 In this report, we describe a unique presentation, for the first time, of corneal manifestations in PLAID.
CASE REPORT
A 21-year-old woman with a diagnosis of PLAID was referred to the Cornea Clinic for evaluation of her long-standing ocular symptoms. Since a few months after birth, the patient had experienced repeated episodes of ocular inflammation resulting in bilateral peripheral corneal pannus inferotemporally with sectoral conjunctivitis, episcleritis, and elevated limbal ridges. These episodes were accompanied by systemic manifestations, most prominently epidermolysis bullosa and interstitial lung disease.
To treat both systemic and ocular manifestations of the disease and to avoid side effects of chronic use of steroids, systemic IL-1b receptor antagonist (IL-1Ra; anakinra) treatment had been started at 14 years of age with considerable improvement; however, it was discontinued 4 years later because of systemic infection.
Upon presentation to us, the patient was complaining of symptoms of ocular discomfort including photophobia, redness, foreign body sensation, and tearing in both eyes. Eye examination revealed conjunctival injection and fibrosis with 360 degrees of corneal scarring and superficial neovascularization. There was .50% thinning in the peripheral cornea bilaterally with the central corneas looking clear and healthy bilaterally. Furthermore, anterior scleritis and small corneal infiltrates devoid of overlying epithelium suggested active disease.
To prevent disease progression and considering the side effects of systemic IL-1Ra, including further immune suppression, treatment with topical 2.5% IL-1Ra (anakinra) was started resulting in partial symptomatic improvement within 2 months. Eight months later, the patient came to us during a systemic exacerbation of the disease complaining of severe eye pain and redness; ocular examination revealed progression of corneal scarring with multiple curvilinear infiltrates and overlying epithelial defects, indicating active ocular disease (Fig. 1) . Oral prednisone 40 mg/d was administered to treat the active disease, leading to systemic and ocular disease abatement.
DISCUSSION
Ocular PLAID is a bilateral chronic recurrent autoinflammatory disease of the ocular surface leading to severe and early cicatricial corneal involvement. This complex systemic immune condition links a persistent state of inflammation to a severe systemic immunodeficiency state. It is characterized by unprovoked episodes of inflammation in the absence of high-titer autoantibodies or antigen-specific T cells, distinguishing it from the classical autoimmune diseases. Therefore, this dysregulation of the innate immune system, mainly associated to high IL-1b secretion, represents a significant therapeutic challenge.
IL-1b overexpression has been associated with several other ocular inflammatory disorders such as uveitis, dry eye, allergy, and chemical burns. [2] [3] [4] [5] Overexpression of IL-1b induces activation and migration of inflammatory cells to the ocular surface, where they contribute to tissue damage and neovascularization. It also promotes apoptosis in corneal fibroblasts and keratocytes resulting in corneal thinning and alteration in wound healing. 2 IL-1b induces increased expression of neuronal growth factors leading to hyperalgesia and chronic pain, which is responsible for a positive neuroinflammatory feedback facilitating further tissue injury. 6 In addition to the persistent inflammation, PLAID patients have an increased risk of infection; more than half of the patients have a history of recurrent sinopulmonary infections because of a hypogammaglobulinemia, with decreased B and natural killer cell numbers in the peripheral blood. 7 Thus, the main challenge in treating these patients is to control inflammation while sustaining adequate immune response to microbial pathogens. Although systemic immunosuppressive agents such as corticosteroids and subcutaneous IL-1Ra remain the mainstay in the treatment of PLAID, their side effects, most prominently secondary infection, limit their prolonged use. Topical IL-1 antagonism may serve as an alternative to manage ocular exacerbations of PLAID between the systemic flares. 2 In addition, more selective agents such as PLCg2 inhibitors may serve as novel approaches in the future. 8 
